Billiontoone (NASDAQ:BLLN) Shares Up 10.6% Following Better-Than-Expected Earnings

Key Points

• Shares rose 10.6% after BillionToOne reported EPS $0.34 versus $0.01 expected and revenue of $108.39M (vs. $95.81M est.), with revenue up 83.8% year-over-year and trading volume ~56% above average as the stock traded around $90.
• Analyst sentiment is mixed—six Buys, three Holds and one Sell—resulting in a consensus rating of Moderate Buy and an average price target of $125.29 despite several recent target reductions.
• Institutional investors (notably Adams Street Partners and Baillie Gifford) initiated large positions recently, while the company has a $4.18B market cap, a very high P/E of 432.99, and strong liquidity (quick ratio 11.32, current ratio 11.69).

Billiontoone, Inc. (NASDAQ:BLLN - Get Free Report) shares shot up 10.6% during trading on Thursday following a better than expected earnings announcement. The company traded as high as $88.80 and last traded at $90.0250. 520,768 shares changed hands during trading, an increase of 56% from the average session volume of 333,450 shares. The stock had previously closed at $81.40.

The company reported $0.34 EPS for the quarter, topping analysts' consensus estimates of $0.01 by $0.33. The business had revenue of $108.39 million during the quarter, compared to analysts' expectations of $95.81 million. The business's revenue was up 83.8% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.39) EPS.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the company. Wall Street Zen raised shares of Billiontoone from a "hold" rating to a "buy" rating in a report on Saturday, March 7th. Wells Fargo & Company decreased their price target on Billiontoone from $110.00 to $90.00 and set an "equal weight" rating on the stock in a report on Thursday, March 5th. Guggenheim cut their price target on Billiontoone from $120.00 to $100.00 and set a "buy" rating on the stock in a research note on Monday, March 30th. BTIG Research dropped their price objective on Billiontoone from $140.00 to $130.00 and set a "buy" rating on the stock in a research report on Thursday. Finally, Weiss Ratings reaffirmed a "sell (d)" rating on shares of Billiontoone in a report on Friday, May 1st. Six research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $125.29.

Institutional Investors Weigh In On Billiontoone

Large investors have recently bought and sold shares of the stock. Adams Street Partners LLC acquired a new position in shares of Billiontoone during the fourth quarter worth $140,063,000. Baillie Gifford & Co. acquired a new position in Billiontoone during the fourth quarter worth approximately $103,786,000. Price T Rowe Associates Inc. MD acquired a new position in Billiontoone during the fourth quarter worth approximately $39,717,000. JPMorgan Chase & Co. acquired a new position in Billiontoone during the fourth quarter worth approximately $32,078,000. Finally, Wasatch Advisors LP acquired a new position in Billiontoone during the first quarter worth approximately $29,179,000.

Billiontoone Trading Up 11.7%

The firm's 50 day moving average is $77.51. The company has a market cap of $4.18 billion and a P/E ratio of 432.99. The company has a quick ratio of 11.32, a current ratio of 11.69 and a debt-to-equity ratio of 0.12.

About Billiontoone

BillionToOne NASDAQ: BLLN is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.